FOS Expression in Blood As a LDL-independent Marker of Statin Treatment

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2010 Jul 13

PMID 20619839

Citations 3

Authors

Ju-Gyeong Kang

Ho Joong Sung

Sarah I Jawed

Cynthia L Brenneman

Yesoda N Rao

Salman Sher

Flavia M Facio

Leslie G Biesecker

Arshed A Quyyumi

Vandana Sachdev

Paul M Hwang

Affiliations

Soon will be listed here.

Abstract

Objectives: The expression of FOS, a gene critical for monocyte and macrophage function, can be inhibited by statins through the disruption of a cholesterol-independent signaling pathway. In this pilot study, we hypothesized that blood FOS mRNA levels will be sensitive to statin treatment independent of LDL cholesterol levels.

Methods: Three cohorts at increased risk of or with cardiovascular disease (CVD) were studied. Blood FOS mRNA levels were measured before and after statin treatment or in patients under stable treatment.

Results: Statin treatment for three months significantly reduced blood FOS mRNA and LDL cholesterol levels. However, in subjects with similar LDL levels achieved by different doses of long term statin treatment, there was an inverse relationship between statin dose and FOS expression.

Conclusions: FOS mRNA levels appear to be a sensitive marker of statin treatment that is dissociated from cholesterol levels.

Citing Articles

NaviSE: superenhancer navigator integrating epigenomics signal algebra.

Ascension A, Arrospide-Elgarresta M, Izeta A, Arauzo-Bravo M BMC Bioinformatics. 2017; 18(1):296.

PMID: 28587674 PMC: 5461685. DOI: 10.1186/s12859-017-1698-5.

Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease.

Masud R, Shameer K, Dhar A, Ding K, Kullo I J Clin Bioinforma. 2012; 2:6.

PMID: 22409835 PMC: 3381689. DOI: 10.1186/2043-9113-2-6.

Differentially expressed genes in human peripheral blood as potential markers for statin response.

Won H, Kim S, Bang O, Lee S, Huh W, Ko J J Mol Med (Berl). 2011; 90(2):201-11.

PMID: 21947165 DOI: 10.1007/s00109-011-0818-3.

References

Liebermann D, Gregory B, Hoffman B . AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis. Int J Oncol. 1998; 12(3):685-700. DOI: 10.3892/ijo.12.3.685. View

Liao J, Laufs U . Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118. PMC: 2694580. DOI: 10.1146/annurev.pharmtox.45.120403.095748. View

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

Patino W, Mian O, Kang J, Matoba S, Bartlett L, Holbrook B . Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A. 2005; 102(9):3423-8. PMC: 552911. DOI: 10.1073/pnas.0408032102. View

Sinnaeve P, Donahue M, Grass P, Seo D, Vonderscher J, Chibout S . Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS One. 2009; 4(9):e7037. PMC: 2736586. DOI: 10.1371/journal.pone.0007037. View

Chittenden T, Sherman J, Xiong F, Hall A, Lanahan A, Taylor J . Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization. Circulation. 2006; 114(17):1811-20. DOI: 10.1161/CIRCULATIONAHA.106.628396. View

Biesecker L, Mullikin J, Facio F, Turner C, Cherukuri P, Blakesley R . The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res. 2009; 19(9):1665-74. PMC: 2752125. DOI: 10.1101/gr.092841.109. View

Jain M, Ridker P . Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4(12):977-87. DOI: 10.1038/nrd1901. View

Lavezzi A, Milei J, Grana D, Flenda F, Basellini A, Matturri L . Expression of c-fos, p53 and PCNA in the unstable atherosclerotic carotid plaque. Int J Cardiol. 2003; 92(1):59-63. DOI: 10.1016/s0167-5273(03)00055-x. View

10.

Robinson J, Smith B, Maheshwari N, Schrott H . Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005; 46(10):1855-62. DOI: 10.1016/j.jacc.2005.05.085. View

11.

Marinissen M, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind J . The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell. 2004; 14(1):29-41. DOI: 10.1016/s1097-2765(04)00153-4. View

12.

Libby P, Ridker P, Hansson G . Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54(23):2129-38. PMC: 2834169. DOI: 10.1016/j.jacc.2009.09.009. View

13.

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

14.

Seo D, Ginsburg G, Goldschmidt-Clermont P . Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. J Am Coll Cardiol. 2006; 48(2):227-35. PMC: 7126828. DOI: 10.1016/j.jacc.2006.02.070. View

15.

Wang Z, Ovitt C, Grigoriadis A, Ruther U, Wagner E . Bone and haematopoietic defects in mice lacking c-fos. Nature. 1992; 360(6406):741-5. DOI: 10.1038/360741a0. View